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Abstract
Background: Non-alcoholic fatty liver disease (NAFLD) is one of the most common causes of fatty 
liver, characterized by the accumulation of fat in the hepatocytes in the absence of alcohol consumption. 
The spectrum of this disease ranges from steatosis to hepatitis and fi nally cirrhosis and hepatocellular 
carcinoma. NAFLD pathogenesis is not completely understood but various risk factors like obesity, 
insulin resistance, and metabolic syndromes have been identifi ed. With the rapid increase in obesity and 
diabetes during the past decade, the incidence of NAFLD is on the rise and is predicted to become the 
most common indication for liver transplantation in the future.
Context of the study: The treatment option for NAFLD is limited and mainly focuses on risk factor 
modifi cation like dietary changes and exercise. A major shortcoming of this approach is the lack of 
adherence and non-compliance over time.  Other therapeutic options are available but are limited in 
number and have questionable effi cacy and safety profi les. Thus, new target-oriented therapies are 
needed. 
Results: One such option is using agonists of the farnesoid X receptor (FXR) which are nuclear 
receptors abundantly expressed in the liver and shown to play a key role in various metabolic pathways 
such as bile acid, cholesterol, lipid and glucose metabolism. 
Main focus and conclusions: In this review, we mainly discuss the role of FXR in the pathophysiology 
of NAFLD and how it can be a useful treatment target for such patients.
Review Article
Farnesoid X Receptor Agonist as a new 
treatment option for Non-Alcoholic 
Fatty Liver disease: A Review
Sukhpreet Singh1 and Kusum K 
Kharbanda1-3*
1Research Service, Veterans Affairs Nebraska-
Western Iowa Health Care System, Omaha, Nebraska, 
68105, USA
2Department of Internal Medicine, Molecular Biology, 
University of Nebraska Medical Center, Omaha, 
Nebraska, 68198, USA
3Department of Biochemistry & Molecular Biology, 
University of Nebraska Medical Center, Omaha, 
Nebraska, 68198, USA
Dates: Received: 12 May, 2017; Accepted: 10 June, 
2017; Published: 12 June, 2017
*Corresponding author: Kusum K. Kharbanda, 
Veterans Affairs Nebraska-Western Iowa Health 
Care System, Research Service (151), 4101 Wool-
worth Avenue, Omaha, Nebraska, 68105, USA, Tel: 
+1-402-995-3752; Fax: 1+402-995-4600; E-mail:                                   
https://www.peertechz.com 
Abbreviations
NAFLD: Non-Alcoholic Fatty Liver Disease; FXR: 
Farnesoid X Receptor; NASH: Non-Alcoholic Steatohepatitis; 
HCC: Hepatocellular Carcinoma; CYP7A1: Cholesterol-7-
hydroxylase; LDRL: LDL Receptor; SREBP-1c: Sterol Regulatory 
Element Binding Protein 1c; LDL: Low Density Lipoprotein; 
VLDL: Very Low Density Lipoprotein; FGF: Fibroblast 
Growth Factor; HDL: High Density Lipoprotein; Apo A-1: 
Apolipoprotein A-1; NASH: Non-Alcoholic Steatohepatitis; 
CDCA: Chenodeoxycholic; OCA: Obeticholic Acid
Background
The incidence and prevalence of non-alcoholic fatty liver 
disease (NAFLD) is on the rise with each passing decade and 
at present 25-35% and 5-15% of the general population of 
Western and Asian countries, respectively, are affected by this 
disease [1-3]. The spectrum of NAFLD ranges from benign 
steatosis to non-alcoholic steatohepatitis (NASH) to cirrhosis 
and fi nally to hepatocellular carcinoma (HCC). The exact 
pathophysiology of this disease is not completely understood 
but various risk factors such as obesity, type 2 diabetes mellitus 
and metabolic syndrome have been identifi ed. The prevalence 
of NAFLD is much higher in patients with obesity (75-92%) 
and diabetes (60-70%) compared to the general population 
[4-7]. Most of the NAFLD patients have benign steatosis and 
are asymptomatic. However, 15-40% of such patients may 
progress to NASH which can be life threatening [8]. 15% of 
NASH patients can progress to cirrhosis in 10-15 years [9] and 
cirrhosis increases the risk of HCC by 10% [10,11]. In addition, 
NAFLD increases the risk for various other cancers, particularly 
in the gastrointestinal tract (colon, oesophagus, stomach, and 
pancreas) and extra-intestinal sites (kidney, prostate, breast) 
[12]. With the increase in incidence of NAFLD, the incidence of 
liver transplantation in such patients is also increasing. NASH 
is currently the second leading reason for liver transplantation 
and it is predicted that it will be the leading cause in the 
future [13,14]. With the increasing incidence of NAFLD, it has 
also been reported that hospitalisation and mortality in these 
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patients is not mainly due to liver related causes but also 
due to cardiovascular and renal causes [15-19]. Thus NAFLD 
poses a serious health problem and up until now, no proper 
pathophysiological targeting treatment has been found. 
Treatment is mainly directed towards weight loss and risk 
factor reduction. A weight loss of 3-5% by diet modifi cation and 
exercise has been shown to reduce steatosis while ≥5-7% drop 
in weight has shown to resolve NASH. Greater reductions in 
weight ≥10% may also improve hepatic fi brosis [20]. However, 
the shortcoming of this approach is the lack of adherence and 
non-compliance with time. [20-23]. Thus, an effective and 
safe therapeutic regimen is critically needed.
Farnesoid X receptor (FXR) is a nuclear hormone receptor, 
which is expressed in various organs and tissues, mainly in 
the liver, intestine, kidney, and adrenal cortex [24,25]. It is 
a ligand activated transcription factor, with bile acid being 
the natural ligand to these receptors [26]. These receptors 
are involved in regulating various metabolic pathways such 
as bile acid, cholesterol, and lipid and glucose metabolism 
[27,28]. The expression of FXR is reduced in the liver of NAFLD 
patients [29], and various FXR knockout animal models exhibit 
hepatic steatosis, bile acid accumulation, hyperlipidaemia, 
hyperglycaemia and fi brosis [30-32].  Importantly, these 
conditions are improved by increasing FXR expression [33,34], 
indicating that the FXR agonist could be an effective therapeutic 
option for NAFLD patients. 
Isoforms of FXR
Until now, four FXR isoforms have been identifi ed in 
humans. These four isoforms are derived from a single gene 
(NR1H4) in humans because of differential promoter usage and 
splicing at exon 5. These isoforms are classifi ed as FXR1 (+), 
FXR1(-), FXR2(+) and FXR2(-). FXR1 and FXR2 differ in 
amino acid sequence at their amino terminus and both FXR1(+) 
and FXR2(+) contain a four amino acid (MYTG) insertion in 
the hinge region immediately adjacent to the DNA binding 
domain. This affects their ability to bind to FXR response 
elements (FXRE), thus making them less transcriptionally 
active [35,36]. All four isoforms occur in many tissues but 
FXR1 is predominantly expressed in the liver and adrenals, 
whereas FXR2 is mainly found in the intestine and kidney. In 
most cell types the strongest response was found to be that of 
FXR1 (-). When the response of all four isoforms were studied, 
it was found that in liver cells, FXR induced BSEP (bile salt 
export pump) stimulating response was FXR1(-) > FXR2(-) 
> FXR1(+) > FXR2(+); for SHP (small heterodimer partner) it 
was FXR1(-) = FXR2(-) > FXR1(+) = FXR2(+).  However, all 
of the isoforms showed the same effi ciency for OST  (organic 
solute transporter ) expression. Also, the differential response 
for all the isoforms in intestinal cells for FGF19 (fi broblast 
growth factor 19) and IBABP (intestinal bile acid binding 
protein) expression was found to be somewhat similar to BSEP, 
with FXR1 (+) and FXR2(+) displaying same potency i.e., the 
order of magnitude for up regulation was FXR1(-) > FXR2(-) 
> FXR1(+) = FXRv2(+) [37]. In a mouse model study addressing 
the role of FXR1 (-) and FXR2(-) on bile and lipid metabolism 
showed that these most active isoforms differentially regulate 
Cyp8b1and SHP expression. Both isoforms have been shown to 
reduce the elevated total plasma cholesterol levels, with FXR1 
(-) being more effective than FXR2 (-), but neither completely 
normalized cholesterol levels to those seen in wild type mice 
[38-40]. FXR2(-) was shown to differ from FXR1 (-) in their 
N-terminal parts with a 37 amino acid extension which must 
have contributed to conformational changes in the FXR protein 
and its transcriptional activity. Despite the identifi cation 
of the four FXR isoforms, their detailed physiological roles, 
coregulator recruitment and DNA-binding in different tissues 
are still not clearly understood. Thus, for the purpose of this 
review, FXR will refer to all four isoforms.
Effects of FXR on multiple metabolic pathways
In addition to regulating various metabolic pathways 
as indicated above [27, 28], FXR also affects infl ammation, 
fi brosis, liver regeneration and atherosclerosis [41,42]. 
Role of FXR in bile acid metabolism
The main role of FXR is to protect the hepatocytes by 
preventing accumulation of bile acid by inhibiting bile acid 
synthesis, reabsorption, and accelerating its excretion mainly 
at the hepatocytes and enterocytes level. Bile acid is a natural 
ligand for FXR and upon binding causes FXR activation 
which, in turn, leads to the suppression of cholesterol-7-
hydroxylase (CYP7A1), a key enzyme in bile acid synthesis. 
CYP7A1 is not directly suppressed by FXR, rather FXR increases 
the expression of the small heterodimer partner (SHP), which 
in turn inhibits the CYP7A1 gene [43,44]. FXR in enterocytes, 
upon activation by bile acid, induces fi broblast growth factor 
19 (FGF 19) which upon binding to FGF4 receptors, causes 
inhibition of CYP7A1 via the JNK pathway [45-47]. FXR also 
regulates the enterohepatic circulation of bile acid. It does so 
by inhibiting the Na+-dependent taurocholate transporter 
which is responsible for bile acid transport, thus reducing 
uptake by the hepatocytes as well as up regulates the bile salt 
export pump, thus increasing bile acid export. FXR activation 
in enterocytes reduces the expression of apical sodium-
dependent bile salt transporter which is mainly responsible 
for bile acid absorption at the terminal ileum, thus inhibiting 
its reabsorption. Moreover, the activation of FXR increases the 
expression of the cytosolic intestinal bile acid-binding protein 
(I-BABP), an important transport protein in the intestine 
which transports the BAs across the enterocytes and portal 
circulation to the liver [48,49]. Also it increases the expression 
of the organic solute transporter / (OST /), thus secreting 
bile acid into systemic circulation to be excreted via the kidney 
[50]. Thus, FXR activation in hepatocytes and enterocytes 
protect the hepatocytes from toxic accumulation of bile acids.
Role of FXR in cholesterol and lipid metabolism
Previous research has shown that bile can modulate 
cholesterol and lipid metabolism [51, 52]. The expression 
of FXR is reduced in the liver of NAFLD patients [29]. The 
relevance of FXR in modulating cholesterol homeostasis is 
evident from FXR knockout mice that exhibit increased hepatic 
and serum cholesterol levels [53,54]. FXR activation increases 
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fecal cholesterol excretion by inhibiting intestinal cholesterol 
absorption [55,56]. Further, FXR activation decreases hepatic 
cholesterol uptake via increasing the expression of low 
density lipoprotein (LDL) receptor (LDLR), scavenger receptor 
class B type I and decreasing cluster differentiation protein 
36 expression [54,57]. FXR activation also increases liver 
cholesterol excretion by increasing the expression of ATP-
binding cassette G5/8 (ABCG5/G8), the cholesterol effl ux 
transporter [58]. 
NAFLD patients exhibit high triglyceride levels due to the 
decreased FXR and increased SREBP-1c expression [29]. FXR 
activation signifi cantly impacts lipid synthesis, mainly by 
decreasing the expression of the sterol regulatory element 
binding protein 1c (SREBP-1c) and its enzymes which are the 
main regulator in lipogenesis [59]. In addition, FXR activation 
increases the clearance of LDL, very low density lipoprotein 
(VLDL) and chylomicrons by activation of lipoprotein 
lipase [60], and increasing VLDL receptor expression [61]. 
Furthermore, FXR activation results in the induction of the 
peroxisome proliferator activated- receptor which increases 
fatty acid oxidation [62]. Also it increases the secretion of 
FGF21 which decreases lipogenesis by inhibition of SREBP-1c 
[63,64]. 
Role of FXR in glucose homeostasis
FXR also plays a key role in a glucose homeostasis. 
FXR activation improves insulin sensitivity and decreases 
gluconeogenesis by suppression of phosphoenolpyruvate 
kinase and glucose-6-phosphatase which are the key enzymes 
required for gluconeogenesis [32, 65]. Further, by increasing 
FGF21 secretion, FXR induces the phosphorylation of glycogen 
synthase kinase which promotes glycogen synthesis and 
suppresses gluconeogenesis [66,67].  
Anti-infl ammatory and anti-fi brogenic properties
FXR is reported to exhibit anti- infl ammatory and anti-
fi brogenic properties. FXR activation decreases hepatic 
infl ammation by suppressing the nuclear factor kappa B 
pathway [68]. Administration of the FXR agonist in a NAFLD 
animal model reduces various pro- infl ammatory cytokines 
and growth factors [31]. FXR knockout mice have been shown to 
be more susceptible to lipopolysaccharide-induced liver injury, 
thus indicating that FXR has anti- infl ammatory properties 
[68]. 
Anti-tumorigenic properties
FXR is a multi-functional receptor that also exhibits anti-
tumorigenic properties. FXR knockout mice have been shown to 
develop liver tumours with aging [69,70], and FXR expression 
has been found to be signifi cantly decreased in many human 
tumour specimens [71-74].  In FXR knockout mice excessive BA 
accumulation has been considered to have cytotoxic effects, thus 
favouring tumorigenesis [69,70,75]. Also, sharply increased 
BA levels lead to activation of YAP protein and Hippo pathway 
which is a crucial promoter of hepatocarcinogenesis [76-78]. 
NASH, obesity and diabetes mellitus have been considered to 
increase the risk of HCC; thus, by maintaining the homeostasis 
of glucose, lipid and by antagonizing the hepatic infl ammation 
and fi brosis, FXR is believed to impede the progression of NASH 
to cirrhosis to HCC [60]. FXR also promotes liver regeneration by 
activating FoxM1b transcription factor [79]. FXR defi cient mice 
display defective repair ability and delayed liver regeneration 
in an already damaged liver [79,80]. Moreover, it causes the 
inhibition of infl ammatory signalling pathways like NFB and 
STAT3 which play a key role in hepatic damage, fi brosis and 
act as a promoter of liver carcinogenesis [81-83]. Another 
FXR targeted gene is N-myc downstream regulated gene 2 
(NDRG2- tumour suppressor gene). FXR knockout mice and 
human HCC patients have shown to have diminished levels of 
NDGR2 mRNA. FXR agonists or ectopic over-expression of FXR 
leads to the transcriptional induction of the NDRG2 gene [84]. 
Also, FXR has been shown to have a chemoprotective response 
on liver cells by changing the expression of several genes like 
ABCB4, TCEA2, CCL14, CCL15 and KRT13 which may be involved 
in drug effl ux, DNA repair, and cell survival. This characteristic 
is shared by both healthy and tumour cells, thus playing an 
important role in the chemoprotection of healthy hepatocytes 
against genotoxic compounds and at same time reducing 
the response of liver tumor cells to certain pharmacological 
treatments [85].
Due to the FXR defi ciency, hepatocytes are exposed to 
an environment which favours malignant transformation. 
Therefore, changing the FXR silencing or activation of remnant 
FXR may be potential strategies for liver cancer patients. 
Pro-atherosclerotic properties
However, FXR activation has some concerning side effects. It 
increases the susceptibility to atherosclerosis by inhibiting the 
removal of cholesterol from peripheral cells via suppressing the 
expression of apolipoprotein A-1 (Apo A-1), a main constituent 
of high density lipoprotein (HDL) [86,87]. FXR activation also 
suppresses the paraoxonase 1 enzyme which plays a key role 
in inactivation of pro-atherogenic lipids [88,89]. Finally, FXR 
suppresses the action of proprotein convertase subtilisin/
kexin 9 that promotes degradation of LDL [90,91]. Two phase I 
studies conducted in healthy individuals looking at the effects 
of FXR activation by OCA reported a decrease in HDL and 
increase in LDL cholesterol, regardless of the dose of OCA (5, 10 
or 25 mg daily) after 14-20 days of treatment [92]. Similarly, 
treatment of NAFLD patients with OCA caused a 10% increase 
in total cholesterol, a 20% increase in LDL cholesterol and a 
5% decrease in HDL cholesterol. Comparable reduction in HDL 
cholesterol was also reported in PBC patients treated with OCA. 
These effects are reversible after drug discontinuation [93-95]. 
These adverse side effects of FXR activation raise concern for 
its utility in treating NAFLD patients. The signifi cance of these 
changes on cardiovascular outcomes needs to be explored more 
in any OCA based treatment strategy.
Role of FXR agonist in NAFLD treatment
At present there is no effective therapy for NAFLD and 
the treatment options are mainly directed towards lifestyle 
modifi cation in the form of diet modifi cation, weight loss and 
exercise as these factors improve obesity and insulin sensitivity. 
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However, patient’s adherence to life style modifi cation and 
compliance falls with time [96-98]. Liver transplantation is 
the only option left for NASH patients with cirrhosis. However, 
even after transplantation there is risk of recurrence of disease 
and cardiovascular complications [99]. 
As discussed, FXR play a key role in bile acid, cholesterol, 
lipid and glucose homeostasis; and also it is shown to have 
anti-infl ammatory and anti-fi brogenic properties. These 
actions of FXR make it a suitable therapeutic option for NAFLD 
patients.
FXR agonist (GW4064) treatment in a preclinical study 
conducted in a genetically obese mouse with insulin resistance 
improved insulin sensitivity and glucose clearance when 
compared to controls [100]. Further, treatment of FXR+/+ and 
FXR-/- mice with GW4064 showed a signifi cant decrease of 
plasma glucose and fatty acids in FXR+/+ mice [67]. Similar 
effi cacy of the FXR agonist was observed in a diabetic mouse 
model [67]. GW4064 increases the expression of p62/SQSTM1 
and nuclear factor erythroid 2-related factor-2 (Nrf2) 
resulting in the induction of various antioxidant and anti-
apoptotic molecules [101]. Furthermore, administration of 
an FXR agonist (WAY 362450) to a methionine and choline 
defi cient, diet-induced animal model of NASH, exhibited a 
signifi cant reduction in liver transaminases enzymes. Also, 
a signifi cant decrease in hepatic fi brosis and infl ammatory 
cell infi ltration and cytokines were observed [34]. Recently, a 
novel, non-steroidal FXR agonist, PX20606, has been shown 
to have anti-fi brotic and vasodilator properties and lowers 
portal hypertension [102]. A newly found non-bile steroidal 
dual ligand for FXR and GPBAR1 receptors, BAR502, reverses 
high-fat diet induced steatohepatitis in mice by promoting the 
browning of adipose tissue [103]. All of these results indicate 
that the FXR agonist could be an effective treatment option for 
NAFLD patients.
Of all the synthetically derived FXR agonists, the most 
clinically advanced is INT-747/Obeticholic acid (OCA) which 
is a semi-synthetic derivative of a natural bile acid analogue, 
chenodeoxycholic acid (CDCA), with an affi nity 100 times 
greater than CDCA [104, 105]. Preclinical studies of OCA 
in the Zucker (fa/fa) rat, a NAFLD rat model, resulted in 
reduction of gluconeogenesis, lipogenesis and improvement 
of insulin resistance and hepatic steatosis [33]. In a rat model 
of thioacetamide-induced cirrhosis, OCA reduced hepatic 
infl ammation and fi brosis and also decreased intrahepatic 
vascular resistance and improved portal hypertension [106]. In 
a rabbit model of high fat diet-induced NAFLD, administration 
of OCA resulted in an improvement in visceral fat and 
plasma glucose levels [107]. In addition, OCA administration 
reduces liver transaminases, IFN- gamma and TNF- in an 
autoimmune hepatitis mouse model [108]. FXR activation 
has been shown to promote hepatic amino acid catabolism 
and ammonium clearance via ureagenesis and glutamine 
synthesis [109]. OCA also decreases intestinal infl ammation in 
various colitis animal models [110]. In an animal model with 
advanced cirrhosis, treatment with OCA signifi cantly reduced 
gut bacterial translocation [111]. Additional miR-21 ablation 
with FXR activation by OCA ameliorated NASH suggesting that 
a multi-receptor targeting therapy could be the most effective 
treatment strategy [112].
OCA is the only FXR agonist which has been examined in 
clinical trials on NAFLD patients. Its role has been investigated 
in two large randomized controlled trials (NCT00501592 and 
NCT01265498). The fi rst trial was conducted on NAFLD and 
type 2 diabetes mellitus patients (NCT00501592), in which 
patients were randomly distributed in any of the three groups 
receiving placebo or 25 mg or 50 mg OCA for a period of 6 
weeks. It was noticed that patients receiving 25 mg and 50 mg 
of OCA showed improvement in insulin sensitivity by 28% and 
21%, respectively, while it worsened in the placebo arm by 5%. 
Weight loss was noticed in both the OCA groups but hepatic 
fi brosis improved only in patients on the 25 mg OCA regimen. 
An increase in alkaline phosphatase, with a decrease in alanine 
transaminase and -glutamyltransferase levels was noticed in 
both OCA-treated groups. While aspartate transaminase levels 
remained stable in all, a decrease in HDL and an increase in 
LDL were noticed in patients treated with 50 mg OCA [113].
Recently, OCA treatment was used in another large trial, 
the FLINT trial (NCT01265498), which included NASH patients 
with or without cirrhosis. In this multicentre trial, 283 patients 
were randomly distributed in either placebo or 25 mg OCA arm 
for 72 weeks. Here 45% of the patients in the OCA arm and 21% 
of the patients in the placebo arm met the primary outcome of 
the study which was determined to be a drop of 2 points in the 
NAFLD activity score. In addition to this, 35% of the patients in 
the OCA arm and 19% in the placebo arm showed a reduction 
in hepatic fi brosis. OCA group patients showed a reduction in 
body weight, liver transaminases and systolic blood pressure 
but an increase in plasma glucose levels and insulin resistance. 
Pruritus was noticed as the main side effect in the patients in 
the OCA group [114]. A Phase 3, Double-blind RCT Multicenter 
Study is ongoing to evaluate the safety and effi cacy of OCA in 
NASH patients (ClinicalTrials.gov Identifi er: NCT02548351). 
This trial evaluates the effect of OCA compared to placebo on 
liver histology in non-cirrhotic NASH patients with stage 2 or 
3 fi brosis. 2065 patients are randomized in 1:1:1 to placebo, 
10 mg or 25 mg OCA.  An interim analysis is to be done at 18 
months and the study is expected to end in 6 years (https://
clinicaltrials.gov/ct2/show/NCT02548351).
All of the preclinical animal/human and clinical human 
studies suggest that FXR agonist/OCA can be a potential 
therapeutic option in NAFLD patients. However, OCA produces 
pro-atherogenic effects that can be a concern for NAFLD patients 
with a high risk for cardiovascular adverse events. Therefore, 
long term larger clinical trials are required to determine its 
effi cacy and safety. Further, combination therapies with FXR 
agonist and agents that prevent atherosclerosis are warranted. 
Conclusions
The FXR agonist appears to be an attractive drug due to its 
pleiotropic actions of regulating various metabolic pathways. 
They play a critical role in bile acid, lipid, cholesterol, and 
glucose homeostasis. In addition, they also have anti-
infl ammatory and anti-fi brogenic properties. The data 
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presented from various preclinical and clinical studies suggest 
that it can be a good therapeutic option in the prevention and 
treatment of NAFLD. However, several undesirable results 
such as a decrease in plasma HDL is concerning. Therefore, 
larger, long-term clinical trials are required to determine its 
effi cacy and safety. Further, combination therapies with FXR 
agonist and agents that prevent atherosclerosis are warranted. 
Furthermore, we should continue to gain a better understanding 
of NAFLD pathogenesis such that additional molecular targets 
and cellular pathways could be identifi ed for developing other 
novel therapeutic regimen(s) in the future. 
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